A 2-month-old premature infant developed a spontaneous chylothorax. Medical therapy (chest tube drainage, parenteral alimentation) and thoracic duct ligation at 103 days of age had no effect. Drainage ceased during an octreotide infusion. The effusion recurred after octreotide was stopped, and responded completely to a longer course of therapy. Octreotide offers a substantial advantage over current medical management to some babies with spontaneous chylothorax.
INTRODUCTION
Neonatal chylothorax is an uncommon, serious clinical problem. It can occur postoperatively because of injury to intrathoracic lymphatics 1 or can occur spontaneously. 2, 3 Neonatal chylothorax causes substantial morbidity and occasional mortality. 4 Several case reports have described successful treatment of postoperative chylothoraces with somatostatin or its synthetic equivalent, octreotide, in two adults and 11 children. [5] [6] [7] [8] [9] [10] [11] [12] We report successful octreotide treatment of a spontaneous chylothorax in a 2-month-old premature infant.
CASE REPORT
This 960 g, 26-week premature infant received surfactant in the delivery room. She required ligation of a patent ductus arteriosus on the 6th day of life. Chest X-rays displayed no sign of pleural fluid. She received ventilatory support until day 27 and supplemental oxygen until the 43rd day of life.
Gradual respiratory deterioration developed 3 weeks later. A chest X-ray on day 65 of life identified a left pleural effusion. Thoracentesis yielded 50 ml of milky fluid with a lymphocytic pleocytosis and elevated triglycerides. Continued production of copious volumes of fluid mandated placement of a chest tube.
Enteral feedings were replaced by intravenous nutrition. Chyle drainage continued unabated for the next 5 weeks. Thoracic duct ligation on day 103 had no effect, and drainage of about 300 ml/ day persisted. We began treatment with subcutaneous octreotide, 4 mg/kg/day, on day 109 and cautiously increased the daily dose, changing to continuous intravenous infusion on day 111. At a dose of 24 mg/kg/day, drainage decreased markedly, and by day 120 drainage was 5 ml/day. No pleural fluid was visible on X-rays from days 120 and 121. We resumed enteral feedings on day 121 without change in chest tube output, and began tapering the drug the next day. The chest tube became dislodged the following day and was not replaced.
Left-sided pleural fluid again was apparent on chest X-rays beginning 1 day later. We replaced the chest tube in response to worsening respiratory status and opacification of the left hemithorax 9 days later, obtaining about 70 ml of fluid, and resumed treatment with octreotide at 24 mg/kg/day. We continued enteral feedings of breast milk. The opacification improved, but a moderate-sized loculated effusion persisted. There was no further drainage from the chest tube. We began tapering the drug on day 137 and discontinued therapy 8 days later. X-ray signs of loculated pleural fluid had resolved by the 148th day of life. The baby did well thereafter.
DISCUSSION
Chylothorax in our patient developed at 34 weeks gestational age, more than 2 months after ligation of a PDA. It likely represents an analog of congenital chylothorax. Congenital chylothorax is an uncommon, potentially fatal problem. Treatment options are limited and unsatisfactory. Conventionally, a thoracentesis is performed and the fluid is aspirated from the chest. This treatment occasionally suffices. Usually, the fluid re-accumulates, necessitating placement of a chest tube. Daily fluid output from the chest tube can reach several hundred ml/kg. This fluid contains large numbers of lymphocytes and has protein content equal to that of plasma. Protein loss compromises nutrition, and the loss of lymphocytes can cause lymphopenia. 12 Nutrition is further compromised by lack of enteral feedings. The prolonged use of parenteral alimentation carries its own risks: infection from the indwelling line, liver injury, and gut atrophy caused by lack of enteral substrate. Further, there are mechanical problems with the chest tubes themselves. These tubes often become obstructed, require multiple replacements, and increase the risk of infection.
They cause substantial discomfort, and can require treatment with sedative and analgesic drugs. Drainage of large amounts of fluid from the chest may cease within days, but often persist for months. Prolonged drainage prompts surgical treatment: ligation of the thoracic duct (often unsuccessful in our experience) or pleurodesis procedures to produce scarring between visceral and parietal pleura. Some babies with persistent chylothoraces (15% in one reported series 13 ) eventually die, usually from complications of therapy. Except for the addition of parenteral nutrition, this therapeutic approach has not changed substantially for more than 50 years. 14 
Somatostatin
15 and its therapeutic analog octreotide 16 reduce lymph flow from surgically created thoracic duct injuries in dogs. Case reports describe similar results in two adults and 11 children who had postoperative chylothoraces. [5] [6] [7] [8] [9] [10] [11] The youngest patient treated was a 14-day-old infant. There have been no reports of recurrent chyle accumulation or significant adverse effects of therapy. Octreotide appears to offer a very attractive alternative to conventional therapy for postoperative chylothoraces.
The extant literature contains only uncontrolled case reports. Although chylothoraces appear to respond to octreotide, improvement may reflect the natural history of these effusions. The prompt resolution of this baby's effusion with initial octreotide therapy was consistent with either treatment effect or spontaneous improvement. The recurrence of chylothorax after stopping the drug and complete resolution after resuming treatment provide good evidence that octreotide was responsible for ending chyle leakage.
Reported durations of octreotide therapy for postoperative chylothoraces range from 3 to 9 days. Pleural fluid drainage had ceased in our patient after 7 days of treatment with 24 mg/kg/day, but the effusion recurred after we tapered treatment. Resuming therapy for 5 more days produced complete resolution. Spontaneous chylothoraces may need a longer duration of treatment than do postoperative lesions. Therapy with octreotide has minor side effects. Our patient had brief hyperglycemia when treatment began. It did not recur with increasing doses of octreotide or when the drug was restarted. Feedings were maintained during the second course of therapy and were briefly interrupted because of emesis, a known adverse effect of treatment.
Compared to conventional therapies, octreotide provides much more rapid resolution of postoperative chylothoraces with fewer potential complications. Based upon our results, it appears that the drug can also provide an improved approach to treating congenital chylothoraces in neonates. However, the pathophysiology of congenital chylothorax ranges from focal lymphatic leaks to diffuse weeping of lymph from the entire pleural surface. 17 It is likely that some congenital chylothoraces will not respond to octreotide.
